You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.


Complex Patient Care Topics in Hematologic Malignancies

  1. Clinical trials of CAR T cell therapies have demonstrated that patients are most likely to develop signs and symptoms of cytokine release syndrome during which of the following timeframes?
    Immediately upon infusion
    1 to 14 days after infusion
    15 to 21 days after infusion
    22 to 30 days after infusion
  2. For what duration of time do both patient and caregiver need to remain in close proximity to the cell therapy center following CAR T cell infusion?
    3 days
    1 week
    1 month
    3 months
  3. A 69-year-old patient received a CAR T cell infusion 1 week ago. Significant decline in the patient's performance on serial handwriting evaluation would raise suspicion of which of the following adverse events associated with CAR T cell therapy?
    Cytokine release syndrome (CRS)
    Engraftment syndrome
    Febrile neutropenia
    Immune effector cell associated neurotoxicity syndrome (ICANS)